New Zealand Cuts Medicinal-Cannabis Export Licence Times to 6.4 Working Days

Export licences are now clearing in 6.4 working days

New Zealand’s medicinal-cannabis export bottleneck has moved from complaint to measurement. The government said on April 14 that medicinal-cannabis export licences issued by Medsafe since January 1, 2026 have taken an average of 6.4 working days to process. That is down from 10.0 working days in 2024-25 and 22.5 working days in 2022-23.

That is news because this part of the system is not theoretical. For relevant consignments, a medicinal-cannabis licence holder still needs a controlled-drug export licence before product can leave the country. In practical terms, that means every delayed approval can hold up an outbound shipment, postpone payment, and test a foreign buyer’s confidence that New Zealand can deliver on schedule.

The gain is large enough to matter operationally. A fall from 22.5 working days to 6.4 does not just shave time off an internal compliance calendar. It reduces the gap between a product being ready to move and the point at which it can actually be shipped. In export industries, that is where cash-flow pressure often sits. Product has been grown, processed, stored, and quality checked, but revenue still waits behind paperwork.

The timing is also useful now because New Zealand has spent the past two years arguing that export settings needed to improve. The same government update that published the new processing-time figure also said cannabis-flower export volumes rose from 49.0 kilograms in 2021 to 2,310.3 kilograms in 2025. That is a sharp change in scale. Once volumes rise that far, licence turnaround stops being an administrative detail and becomes a live operating variable.

The point is not that New Zealand has suddenly become a large global supplier. It has not. The point is that one of the clearer domestic frictions inside its medicinal-cannabis system is now moving in the right direction, and there is enough official data to show it.

The July 2024 rule rewrite is finally visible in day-to-day shipping

The faster export clock did not appear in isolation. It follows a rule change package that took effect on July 5, 2024 and was designed to make the medicinal-cannabis scheme more usable for export-oriented businesses.

Before that change, parts of the framework were built too heavily around the standards required for supplying the New Zealand market itself. That sounds reasonable until an export-only business is caught by requirements aimed at domestic patient protection even when the product is not being sold to New Zealand patients. In those cases, regulation can stop being a safeguard and start becoming duplication.

The 2024 changes reduced some of that mismatch. Government guidance said export-only products and ingredients no longer had to meet certain minimum quality standard requirements that apply inside the domestic medicinal-cannabis scheme. The package also adjusted export settings and simplified parts of the licensing structure. In plain terms, some products made only for overseas sale no longer had to clear every domestic-facing hurdle first, and some businesses faced less licence complexity in getting production and export activities aligned.

That matters because medicinal-cannabis exports are not a single approval event. A business may need cultivation authority, manufacturing authority, supply-chain controls, batch testing, and then shipment-specific export permission. Even a well-run operator can lose time if those layers are not coordinated. The result is not just frustration. It is missed shipping windows, stale inventory plans, and a weaker reputation with overseas counterparties that can buy from other countries.

Health guidance still makes clear that export mechanics remain controlled. Relevant consignments require controlled-drug export licences, and overseas receiving countries may require their own permits or approvals before a shipment can lawfully enter. So the current improvement does not mean exporters are free from bureaucracy. It means one domestic step that used to slow the cycle has become materially quicker.

That distinction is important. The 6.4-day figure is not evidence that every export can move in under a week from warehouse to aircraft. It is evidence that the New Zealand part of the permission chain has become faster on average. For operators, that can be the difference between building a dependable export schedule and treating each shipment as an administrative gamble.

There is also a more basic point beneath the rule rewrite. Countries that want medicinal-cannabis industries often say they support exports, but support can remain abstract if the regulatory design still behaves as if all product will stay at home. New Zealand’s 2024 changes were an attempt to reconcile those positions. The new processing-time data is the first simple indicator that the policy direction is showing up where businesses feel it most clearly, which is in shipment execution.

Faster paperwork matters because New Zealand still needs offshore demand

The deeper reason this story matters is that New Zealand’s domestic medicinal-cannabis market was never expected to carry the whole industry. Cabinet papers and supporting policy material published by the government said that directly: the local market is too small to sustain the sector on its own. Export access was therefore not an optional upside. It was part of the model from the start.

That framing helps explain why a licensing metric deserves attention. If offshore sales are necessary for scale, then export friction becomes a growth constraint rather than a clerical nuisance. A country can have licensed cultivators, manufacturers, and a compliant scheme on paper, but if export permissions arrive too slowly the economics still narrow.

The current public list of medicinal-cannabis licence holders shows 44 operators who agreed to publication as of mid-April. That is not a full census of every participant, because publication depends on consent, but it gives a credible picture of a real operating base. For that visible group, and likely for some not named publicly, the export question is immediate. A small domestic market cannot absorb unlimited cultivation output, processing capacity, or fixed compliance costs.

The domestic picture also remains import-heavy. In an official information response published in late 2025, the Medicinal Cannabis Agency said it had 80 product-related applications as of October 6, 2025. Of those, 64 related to dried flower, and 67 were for imported products or imported cannabis-based ingredients. That means the local patient market still relies heavily on goods or ingredients sourced from abroad even while New Zealand’s own producers are working to expand exports.

This is not contradictory. It shows a market still in formation. Imports can dominate the domestic shelf because foreign producers already have established products, product registrations, manufacturing scale, or lower costs. Local firms, meanwhile, may need export revenue to make their facilities viable while they build a stronger place in the home market. In that environment, faster export licensing helps stabilise businesses that are otherwise caught between limited domestic demand and global competition.

The effect is likely to be felt unevenly across the sector. Cultivators and manufacturers with export channels gain first, because they are the ones converting finished stock into overseas shipments. Contract growers and ingredient suppliers gain indirectly if buyers are more willing to commit to production runs that have a clearer route out of the country. Foreign partners gain from better predictability. Domestic patients may not see an immediate price or product effect, because the bottleneck being eased sits in exports, not prescribing or reimbursement.

There is also a near-term regulatory tailwind at the plant-input level. On May 4, the government updated its hemp guidance to confirm that from May 28, 2026, the industrial-hemp licensing scheme will be revoked and replaced by a permission-based regime. The same guidance says hemp can be sold or supplied into the Medicinal Cannabis Scheme without a hemp licence. That does not rewrite medicinal-cannabis export law, and hemp is a distinct regulatory category. But for businesses that work across cultivation and upstream plant supply, it removes another layer of licensing friction just weeks from now.

Taken together, the signal is not that New Zealand has solved medicinal cannabis. It is that the state is finally making parts of the production-to-export chain easier to use in a sector where bureaucratic delay can quickly become commercial weakness.

Single-digit export approvals are progress, but not yet a settled market advantage

There is a temptation to treat the 6.4-day figure as proof that New Zealand’s medicinal-cannabis export model is now working smoothly. That would go too far.

An average processing time is useful, but averages conceal variation. They do not show whether some products, destinations, or documentation packages still move much more slowly than others. They do not show how often exporters must pause because an importing country is not ready, because a customer changes specifications, or because batch release timing shifts. And they do not tell the market whether the current speed will hold if application volumes keep rising.

Nor does a faster export licence answer the harder commercial questions. It says nothing on its own about global price pressure in dried flower, the strength of New Zealand brands abroad, the margins available to contract manufacturers, or the depth of patient demand at home. A more efficient permit process can improve execution while leaving competition brutally intact.

That said, this development should not be dismissed as a small bureaucratic win. In regulated cannabis markets, industries are often judged by headline reforms long before those reforms reach daily operations. The important feature of the New Zealand update is that it is measurable, current, and tied to a real choke point. A sector that needs exports to scale is now moving one of its core permissions in single-digit working days rather than three or four weeks.

That changes the conversation. It gives companies, policymakers, and foreign counterparties something firmer than a promise. It suggests that the 2024 rule changes were not just permissive on paper but capable of improving how shipments actually leave the country. It also gives a clearer standard for what comes next. If the government wants the medicinal-cannabis sector to be treated as a credible export industry, then this faster pace has to persist through a full year, through higher volume, and across a broader range of commercial situations.

The real test is persistence. New Zealand does not need perfection here. It needs consistency strong enough that exporters can plan around the regulator instead of planning around delay. If that single-digit turnaround holds, the country will have done something more valuable than announce support for medicinal-cannabis exports. It will have made support visible at the loading dock, which is where industrial policy stops being language and starts becoming trade.